Clinical Development Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

Clinical Development Stocks Recent News

Date Stock Title
May 31 MORF Morphic to Participate in Jefferies Global Healthcare Conference
May 31 TGTX TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 30 NXTC NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 30 BLRX BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide
May 30 SAGE Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30 TGTX Despite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 years
May 30 BLRX BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
May 29 AEZS Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
May 29 BBIO BridgeBio reports additional positive data for acoramidis in ATTR-CM
May 29 BBIO Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
May 29 SAGE Baird predicts steady growth for SAGE Therapeutics at $15 target
May 29 AEZS Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger
May 29 SAGE American downgraded, United upgraded: Wall Street's top analyst calls
May 29 SAGE Sage Therapeutics dips after Citi initiates at Sell
May 28 BLRX BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
May 28 TGTX TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 28 BLRX biolinerx GAAP EPS of $0.00 beats by $0.29, revenue of $6.86M beats by $6.52M
May 28 BLRX BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags